ArmA- Lymphoid for Blood Cancers

Phase-Based Progress Estimates
St. Jude Children's Research Hospital, Memphis, TNBlood Cancers+1 MoreCyclosporine - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial is asking people with blood cancer who need a bone marrow transplant to join, to find new ways of preventing severe side effects.

Eligible Conditions
  • Blood Cancers
  • Myeloid Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 1 year post transplant

1 year post transplant
Incidence of Chronic Graft Versus Host Disease (cGVHD)
100 days post transplant
Graft-vs-Host Disease
One-year post-transplantation
Perinatal death
One-year post-transplantation.
Incidence of Leukemic Relapse
one year post-transplantation
Overall Survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

ArmA- Lymphoid
1 of 2
1 of 2

Active Control

32 Total Participants · 2 Treatment Groups

Primary Treatment: ArmA- Lymphoid · No Placebo Group · Phase 2

ArmA- LymphoidActiveComparator Group · 8 Interventions: Cyclosporine, Cyclophosphamide, Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug, Radiation, Drug
ArmB-MyeloidActiveComparator Group · 8 Interventions: Cyclosporine, Fludarabine, Ruxolitinib, Anti-thymocyte globulin (ATG), Methotrexate, Bone marrow infusion, Busulfan, Thiotepa · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year post transplant

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor
406 Previous Clinical Trials
5,302,884 Total Patients Enrolled
Ashok Srinivasan, MDPrincipal InvestigatorSt. Jude Children's Research Hospital
5 Previous Clinical Trials
467 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 21 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has ArmA-Lymphoid received regulatory authorization from the FDA?

"Given that ArmA-Lymphoid is a Phase 2 trial, and thus lacks evidence of efficacy but does have some data indicating safety, our team at Power has assigned it a score of two." - Anonymous Online Contributor

Unverified Answer

How many participants are actively engaged in this clinical experiment?

"Affirmative. reflects that this clinical trial is currently enrolling patients, starting from the 4th of November 2022 and updated as recently as the 7th of November 2022. There are 32 positions available at a single medical facility." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies left to join this clinical experiment?

"Affirmative. Details available on demonstrate that the trial, which was published on November 4th 2022 is actively enrolling individuals. Specifically, 1 research site requires 32 volunteers to participate in this project." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.